Methods of treating prostate cancer with an Anti- psma/cd3 antibody

A prostate cancer and antibody technology, applied in the direction of antibody medical components, anti-animal/human immunoglobulin, antibodies, etc., can solve problems such as drug resistance

Pending Publication Date: 2021-12-03
JANSSEN BIOTECH INC
View PDF10 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

While each of these treatments can delay cancer growth for months and reduce the symptoms the disease produces, the disease eventually becomes resistant to these treatments

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Methods of treating prostate cancer with an Anti- psma/cd3 antibody
  • Methods of treating prostate cancer with an Anti- psma/cd3 antibody
  • Methods of treating prostate cancer with an Anti- psma/cd3 antibody

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0105] Example 1. Materials

[0106] Generation of PSMA cell lines. Expression vectors displaying full-length chimpanzee PSMA (SEQ ID NO:2) or full-length cynomolgus monkey PSMA (SEQ ID NO:3) were generated for use as screening tools to evaluate anti-PSMA leads. The vector was transiently transfected into HEK293F cells. Transfected 293F suspension cells were plated in serum-supplemented growth medium, allowed to become adherent and selected for stable plasmid integration. Single-cell populations were selected by serial dilution, and (PSMAL Antibody (Center) affinity-purified rabbit polyclonal antibody (Cat. No. OAAB02483, Aviva Systems Biology) was used as the primary antibody, while R-PE anti-rabbit secondary antibody (Cat. -116-144, Jackson ImmunoResearch Laboratories, Inc.) and rabbit polyclonal IgG (Cat. No. SC-532, Santa Cruz Biotechnology) as an isotype control) were quantified by FACS for PSMA surface receptor expression.

[0107] SEQ ID NO:2 (full-length chimp...

Embodiment 2

[0114] Example 2. Generation of anti-chimpanzee and anti-human PSMA antibodies

[0115] Panning with recombinant protein. First solution panning of a de novo human Fab-pIX library consisting of VH1-69, 3-23, and 5-51 heavy chain libraries paired with libraries of four human VL germline genes (A27, B3, L6, O12) (Shi, L. et al., J Mol Biol, 2010.397(2): pp. 385-396, WO2009 / 085462) were performed using an alternate panning method in which strands coated with biotinylated chimpanzee PSMA ECD were prepared according to the manufacturer's protocol. One round of phage capture was performed on mycoavidin magnetic beads (Invitrogen, cat. no. 112.05D, lot no. 62992920), followed by a round of phage capture on cynomolgus PSMA-Fc-coated ProtG beads (Invitrogen, cat. no. 10003D) according to the manufacturer's protocol. Phage capture followed by phage capture on Sera-mag Double Speed ​​Neutravidin magnetic beads coated with biotinylated chimpanzee PSMA ECD (Thermo, cat. no. 7815-2104-01...

Embodiment 3

[0134] Example 3. Production and Characterization of Anti-CD3 Antibodies

[0135] Production of anti-CD3 antibodies. The commercial anti-CD3 antibody SP34 (mouse IgG1 isotype anti-human CD3 IgG1 antibody) was humanized by the human framework adaptation method (Fransson et al., JMB, 2010398(2):214-31). To maintain the conformation of CDR-H3, the mouse residues at positions Val38, Gly48, Gly51 and V59 in VL and Ala at position 48 in VH were retained. Add these "back mutations" to your humanization plan. The resulting anti-CD3 variant was designated CD3B146.

[0136] Humanized anti-CD3 antibody binds endogenous cells of primary T cells. Binding of CD3B146 to cell surface CD3ε on primary human T cells and primary cynomolgus monkey CD4+ T cells was tested to assess retention of cross-reactivity. CD4+ T cells purified from peripheral blood of cynomolgus monkeys (Zen Bio, Triangle Research Park, USA) were used. Briefly, binding of anti-CD3 antibody to cell surface CD3ε was ass...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

Bispecific monoclonal antibodies and methods for treating cancer are set forth herein.

Description

[0001] sequence listing [0002] This application contains a Sequence Listing that has been electronically filed in ASCII format and is hereby incorporated by reference in its entirety. Said ASCII copy was created on February 26, 2020, is named JBI6080USPSP1_SL.txt, and is 47,009 bytes in size. technical field [0003] The present invention relates to methods of providing treatment of prostate cancer, including castration-resistant prostate cancer, metastatic castration-resistant prostate cancer, castration-sensitive prostate cancer, and non-metastatic castration-resistant prostate cancer, by administering anti-PSMA / CD3 antibodies. Resistant prostate cancer. Background technique [0004] For men, prostate cancer is the second most commonly diagnosed cancer and the sixth leading cause of cancer death, accounting for 14% (903,500) of all new cancer cases and 6% (258,400) of all cancer deaths in men worldwide. Metastatic prostate cancer is the second leading cause of cancer ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61P13/08A61P35/00C07K16/28C07K16/30
CPCC07K16/2809C07K16/3069C07K2317/31A61K2039/505A61K2039/54A61P13/08A61P35/00A61P35/04A61K9/0019A61K45/06
Inventor T·麦克德维特S·谢蒂H·谢
Owner JANSSEN BIOTECH INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap